Objective Previous studies suggest that inflammation factors are elevated in patients with atrial fibrillation (AF). However, coronary artery disease (CAD), which is often present in the same populations, is related to the raising of iflammation markers， and may present as a confounder in these studies. We therefore examined the association between biomarkers of inflammation and AF in patients with known CAD.Methods We performed a cross-sectional analysis of 670 patients with stable coronary artery diseases from July 2008 to June 2011, 32 of whom had AF. Interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α(TNF-α)， monocyte chemoattractant protein-1 (MCP-1), and fibrinogen (Fg) levels were determined in all the patients. Results In the CAD patients with or without AF, demographic characteristics were different. Age, rate of male, smoking status, history of heart failure, and left atrial volume were higher in patients with AF. In unadjusted analyses, IL-6 was the only biomarker significantly associated with AF (median IL-6 3.54 and 2.36 ng/L in those with and without AF, respectively, P=0.001). Based on multivariate analysis, IL-6 was also the only factor related to AF (Odds Ratio 1.7, 95% CI: 1.32-2.14, P=0.024). Conclusions In patients with CAD， AF is significantly associated with elevated IL-6 levels. No associations were found with other biomarkers, including C-reactive protein, tumor necrosis factor-α, monocyte chemoattractant protein-1, and fibrinogen levels.
Key words
Atrial fibrillation /
Inflammation marker /
Coronary artery disease /
Interleukin-6
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］ Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation［J］. J Am Coll Cardiol, 2003, 41:2197-2204.
［2］ Marcus G M, Yang Y, Varosy P D, et al. Regional left atrial voltage in patients with atrial fibrillation［J］. Heart Rhythm, 2007, 4:138-144.
［3］ Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction［J］. N Engl J Med, 2012,367(14):1310-1320.
［4］ Chugh S S, Blackshear J L, Shen W K, et al. Epidemiology and natural history of atrial fibrillation: clinical implications［J］. J Am Coll Cardiol, 2001, 37:371-378.
［5］ Guize L, Thomas F, Bean K, et al. Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up［J］. Bull Acad Natl Med, 2007,191(4-5):791-805.
［6］ Chimenti C, Russo M A, Carpi A, et al. Histological substrate of human atrial fibrillation［J］. Biomed Pharmacother, 2010,64(3):177-183.
［7］ Chung M K, Martin D O, Sprecher D, et al. C-Reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation［J］. Circulation, 2001,104: 2886-2891.
［8］ Ellinor P T, Low A, Patton K K, et al. C-Reactive protein in lone atrial fibrillation［J］. Am J Cardiol, 2006, 97:1346-1350.
［9］ Goser S, Ottl R, Brodner A, et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy［J］. Circulation, 2005, 112:3400-3407.
［10］ Satoh M, Ishikawa Y, Itoh T, et al. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction［J］. Eur J Clin Invest, 2008,38(2):97-105.
［11］ Conway D S, Buggins P, Hughes E, et al. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation［J］. Am J Cardiol, 2004, 93:1368-1373, A1366.
［12］ Watson T, Arya A, Sulke N, et al. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation［J］. Chest, 2010, 137(4):869-876.
［13］ Goldberg Y H. Relationship between atrial fibrillation and left atrial size［J］. J Am Coll Cardiol, 2008, 51(7):776
［14］ Psychari S N, Apostolou T S, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation［J］. Am J Cardiol, 2005, 95:764-767.
［15］ Luckett L R, Gallucci R M. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice［J］. Br J Dermatol, 2007,156:1163-1171.
［16］ Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation［J］. Circulation, 2004, 109:363-368.
［17］ Gregory M, Marcus, Mary A W, et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study［J］. Am Heart J, 2008, 2:303-309.
［18］ Roldán V, Marín F, Díaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation［J］. J Thromb Haemost, 2012,10(8):1500-1507.
［19］ Hoshi T, Kitagawa K, Yamagami H, et al. Relations of serum highsensitivity C-reactive protein and interleukin-6 levels with silent brain infarction［J］. Stroke, 2005,36:768-772.
PDF(577 KB)
